Pipeline
Pipeline Overview
BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory illnesses

Candidate
Preclinical
Phase 1
Phase 2
Oncology
Targeted Indication1L STK11m NSCLC
Targeted Indication
1L STK11m NSCLC
Phase 1b/2a
Targeted Indication2L NSCLC
Targeted Indication
2L NSCLC
Phase 2
Targeted IndicationAML/MDS
Targeted Indication
AML/MDS
Phase 2
Mipasetamab
uzoptirine
uzoptirine
Targeted IndicationSolid Tumors
Targeted Indication
Solid Tumors
Phase 1
Severe
respiratory
infections
Targeted IndicationSevere respiratory infections in hospitalized patients
Severe respiratory infections in hospitalized patients
Phase 2
Targeted IndicationARDS
ARDS
Preclinical
Fibrosis
Targeted IndicationFibrotic Diseases
Targeted Indication
Fibrotic Diseases
Phase 1
Note : Bemcentinib is also being studied in Investigator Led Trials in glioblastoma, 2L lung cancer, melanoma, pancreatic cancer, and mesothelioma.